See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Didar Yanardag Acik
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7282-0188
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: It has been shown that bcl2, bcl-XL and mcl-1 protein levels are high in chronic lymphocytic leukemia cells, and resultantly, apoptosis does not occur chronic lymphocytic leukemia cells. Apelin and apela are two peptide ligands for a class A G-protein coupled receptor called apelin receptor. Studies have shown that apella inhibits apoptosis by inhibiting apoptotic proteins and activating anti-apoptotic proteins. Proteins and genes involved in apoptosis are valuable for targeted cancer therapy. We hypothesized that serum levels may be increased in patients with chronic lymphocytic leukemia based on the antiapoptotic effect of apelin. We compared serum apelin levels of healthy volunteers and patients with chronic lymphocytic leukemia. We aimed to draw attention to a new molecule worthy of research in targeted cancer treatment. Methods: 42 untreated CLL patients and 41 healthy volunteers were included in the study. Serum Apela levels were measured by by using enzyme-linked immunosorbent assay (ELISA) kits (Dhanghai Sunred Biological Technology co. Ltd), automated ELISE reader (Thermo Scientific, FİNLAND) and computer program (Scanlt for Multiscan F.C.2.5.1) in accordance with the manufacturer’s instructions. Statistical analysis was made by Statistical Package for Social Sciences (SPSS) for Windows 20 (IBM SPSS Inc., Chicago, IL) ve MedCalc programs. Apela and variables related to CLL were correlated with Spearman correlation anlysis test. ROC analysis and Youden index method were used to determine a cut off point for apela. All p-values were 2-sided with statistical significance at 0.05 alpha levels. Results: In our study, we found that serum apela levels were significantly higher in patients with CLL. Conclusions: This study highlights that apela targeting may be a potential therapeutic option for treating CLL. Keywords: Apela; apelinergic system; chronic lymphocytic leukaemia; apoptosis
Keywords
Apela; apelinergic system; chronic lymphocytic leukaemia; apoptosis
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 18 Nov, 2019
Editorial decision: Accept
On 28 Oct, 2019
Editor assigned
On 27 Oct, 2019
Editor invited
On 26 Oct, 2019
No comments provided
Editorial decision: Minor revision
On 24 Oct, 2019
No comments provided
Editorial decision: Minor revision
On 23 Oct, 2019
Editor assigned
On 20 Oct, 2019
Submission checks complete
On 19 Oct, 2019
Editor invited
On 19 Oct, 2019
No comments provided
Editorial decision: Minor revision
On 17 Oct, 2019
Reviewer #2 agreed
On 20 Sep, 2019
Reviewers invited
Invitations sent on 17 Sep, 2019
Reviewer #1 agreed
On 17 Sep, 2019
Review #1 received
Received 17 Sep, 2019
Editor assigned
On 16 Sep, 2019
Submission checks complete
On 15 Sep, 2019
Editor invited
On 15 Sep, 2019
Version 1
Posted 24 Jul, 2019
No comments provided
Editorial decision: Major revision
On 30 Aug, 2019
Review #1 received
Received 27 Aug, 2019
Reviewer #2 agreed
On 13 Aug, 2019
Review #2 received
Received 13 Aug, 2019
Reviewer #1 agreed
On 07 Aug, 2019
Reviewers invited
Invitations sent on 05 Aug, 2019
Editor assigned
On 09 Jul, 2019
Submission checks complete
On 08 Jul, 2019
Editor invited
On 08 Jul, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Didar Yanardag Acik
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7282-0188
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 18 Nov, 2019
Editorial decision: Accept
On 28 Oct, 2019
Editor assigned
On 27 Oct, 2019
Editor invited
On 26 Oct, 2019
No comments provided
Editorial decision: Minor revision
On 24 Oct, 2019
No comments provided
Editorial decision: Minor revision
On 23 Oct, 2019
Editor assigned
On 20 Oct, 2019
Submission checks complete
On 19 Oct, 2019
Editor invited
On 19 Oct, 2019
No comments provided
Editorial decision: Minor revision
On 17 Oct, 2019
Reviewer #2 agreed
On 20 Sep, 2019
Reviewers invited
Invitations sent on 17 Sep, 2019
Reviewer #1 agreed
On 17 Sep, 2019
Review #1 received
Received 17 Sep, 2019
Editor assigned
On 16 Sep, 2019
Submission checks complete
On 15 Sep, 2019
Editor invited
On 15 Sep, 2019
Version 1
Posted 24 Jul, 2019
No comments provided
Editorial decision: Major revision
On 30 Aug, 2019
Review #1 received
Received 27 Aug, 2019
Reviewer #2 agreed
On 13 Aug, 2019
Review #2 received
Received 13 Aug, 2019
Reviewer #1 agreed
On 07 Aug, 2019
Reviewers invited
Invitations sent on 05 Aug, 2019
Editor assigned
On 09 Jul, 2019
Submission checks complete
On 08 Jul, 2019
Editor invited
On 08 Jul, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background: It has been shown that bcl2, bcl-XL and mcl-1 protein levels are high in chronic lymphocytic leukemia cells, and resultantly, apoptosis does not occur chronic lymphocytic leukemia cells. Apelin and apela are two peptide ligands for a class A G-protein coupled receptor called apelin receptor. Studies have shown that apella inhibits apoptosis by inhibiting apoptotic proteins and activating anti-apoptotic proteins. Proteins and genes involved in apoptosis are valuable for targeted cancer therapy. We hypothesized that serum levels may be increased in patients with chronic lymphocytic leukemia based on the antiapoptotic effect of apelin. We compared serum apelin levels of healthy volunteers and patients with chronic lymphocytic leukemia. We aimed to draw attention to a new molecule worthy of research in targeted cancer treatment. Methods: 42 untreated CLL patients and 41 healthy volunteers were included in the study. Serum Apela levels were measured by by using enzyme-linked immunosorbent assay (ELISA) kits (Dhanghai Sunred Biological Technology co. Ltd), automated ELISE reader (Thermo Scientific, FİNLAND) and computer program (Scanlt for Multiscan F.C.2.5.1) in accordance with the manufacturer’s instructions. Statistical analysis was made by Statistical Package for Social Sciences (SPSS) for Windows 20 (IBM SPSS Inc., Chicago, IL) ve MedCalc programs. Apela and variables related to CLL were correlated with Spearman correlation anlysis test. ROC analysis and Youden index method were used to determine a cut off point for apela. All p-values were 2-sided with statistical significance at 0.05 alpha levels. Results: In our study, we found that serum apela levels were significantly higher in patients with CLL. Conclusions: This study highlights that apela targeting may be a potential therapeutic option for treating CLL. Keywords: Apela; apelinergic system; chronic lymphocytic leukaemia; apoptosis
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
Loading...